Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 233 | 2024 | 965 | 34.300 |
Why?
|
Brain Ischemia | 80 | 2021 | 398 | 13.630 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 42 | 2023 | 378 | 7.840 |
Why?
|
Cerebrovascular Disorders | 48 | 2023 | 143 | 5.900 |
Why?
|
Ischemic Attack, Transient | 43 | 2022 | 181 | 5.580 |
Why?
|
Carotid Stenosis | 24 | 2021 | 112 | 5.330 |
Why?
|
Endarterectomy, Carotid | 26 | 2021 | 73 | 4.820 |
Why?
|
Cerebral Hemorrhage | 20 | 2023 | 325 | 3.890 |
Why?
|
Fibrinolytic Agents | 20 | 2016 | 203 | 3.510 |
Why?
|
Humans | 382 | 2024 | 86656 | 3.100 |
Why?
|
Delivery of Health Care | 15 | 2020 | 426 | 2.900 |
Why?
|
Primary Prevention | 11 | 2021 | 85 | 2.490 |
Why?
|
Risk Factors | 77 | 2022 | 5416 | 2.370 |
Why?
|
Stroke Rehabilitation | 12 | 2022 | 41 | 2.360 |
Why?
|
Hospitals | 11 | 2023 | 294 | 2.350 |
Why?
|
Thrombolytic Therapy | 16 | 2019 | 220 | 2.280 |
Why?
|
Intracranial Hemorrhages | 9 | 2023 | 120 | 2.170 |
Why?
|
Aged | 132 | 2023 | 18407 | 2.110 |
Why?
|
Atrial Fibrillation | 12 | 2023 | 288 | 2.110 |
Why?
|
Medicare | 16 | 2023 | 408 | 2.090 |
Why?
|
Cardiovascular Diseases | 23 | 2022 | 827 | 2.080 |
Why?
|
Platelet Aggregation Inhibitors | 16 | 2021 | 134 | 1.970 |
Why?
|
Hospital Mortality | 11 | 2019 | 350 | 1.910 |
Why?
|
United States | 75 | 2023 | 6674 | 1.880 |
Why?
|
Anticholesteremic Agents | 9 | 2023 | 137 | 1.870 |
Why?
|
American Heart Association | 17 | 2023 | 92 | 1.870 |
Why?
|
Neurology | 10 | 2020 | 70 | 1.860 |
Why?
|
Brain | 29 | 2023 | 2220 | 1.820 |
Why?
|
Patient Readmission | 8 | 2023 | 329 | 1.800 |
Why?
|
Male | 190 | 2024 | 40995 | 1.790 |
Why?
|
Tissue Plasminogen Activator | 11 | 2019 | 163 | 1.770 |
Why?
|
Female | 171 | 2024 | 44566 | 1.730 |
Why?
|
Cholesterol, LDL | 14 | 2023 | 223 | 1.690 |
Why?
|
Anticoagulants | 15 | 2023 | 407 | 1.690 |
Why?
|
Islet Amyloid Polypeptide | 7 | 2023 | 25 | 1.680 |
Why?
|
Hypertension | 17 | 2022 | 1142 | 1.680 |
Why?
|
Aged, 80 and over | 56 | 2023 | 6511 | 1.610 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2018 | 508 | 1.530 |
Why?
|
Cerebral Small Vessel Diseases | 2 | 2021 | 7 | 1.520 |
Why?
|
Recovery of Function | 8 | 2018 | 271 | 1.480 |
Why?
|
Heptanoic Acids | 13 | 2014 | 72 | 1.430 |
Why?
|
Health Services Accessibility | 13 | 2020 | 394 | 1.420 |
Why?
|
Practice Guidelines as Topic | 15 | 2019 | 1037 | 1.420 |
Why?
|
Secondary Prevention | 19 | 2022 | 162 | 1.370 |
Why?
|
Hospitalization | 13 | 2023 | 851 | 1.350 |
Why?
|
Pyrroles | 13 | 2014 | 184 | 1.330 |
Why?
|
Cohort Studies | 26 | 2023 | 2765 | 1.330 |
Why?
|
Middle Aged | 110 | 2020 | 25027 | 1.320 |
Why?
|
Emergency Medical Services | 10 | 2014 | 209 | 1.300 |
Why?
|
Severity of Illness Index | 16 | 2018 | 1804 | 1.270 |
Why?
|
Dextroamphetamine | 6 | 2018 | 107 | 1.230 |
Why?
|
Randomized Controlled Trials as Topic | 24 | 2019 | 864 | 1.210 |
Why?
|
Glomerular Filtration Rate | 3 | 2018 | 385 | 1.210 |
Why?
|
Sodium Chloride, Dietary | 2 | 2017 | 11 | 1.190 |
Why?
|
Biomedical Research | 8 | 2020 | 376 | 1.170 |
Why?
|
Neuroprotective Agents | 7 | 2011 | 94 | 1.160 |
Why?
|
Cognitive Dysfunction | 4 | 2023 | 133 | 1.160 |
Why?
|
Alzheimer Disease | 9 | 2023 | 470 | 1.130 |
Why?
|
Risk Assessment | 32 | 2019 | 2261 | 1.110 |
Why?
|
Carotid Artery Diseases | 8 | 2011 | 97 | 1.110 |
Why?
|
Central Nervous System Stimulants | 9 | 2018 | 216 | 1.100 |
Why?
|
Cerebral Infarction | 9 | 2023 | 71 | 1.080 |
Why?
|
Somatosensory Cortex | 9 | 2003 | 129 | 1.060 |
Why?
|
Treatment Outcome | 48 | 2020 | 7982 | 1.060 |
Why?
|
Neurologic Examination | 6 | 2017 | 118 | 1.050 |
Why?
|
Joint Commission on Accreditation of Healthcare Organizations | 4 | 2018 | 13 | 1.050 |
Why?
|
Hypercholesterolemia | 8 | 2018 | 162 | 1.030 |
Why?
|
Academic Medical Centers | 7 | 2020 | 378 | 1.020 |
Why?
|
Emergency Service, Hospital | 10 | 2022 | 484 | 1.010 |
Why?
|
Asymptomatic Diseases | 2 | 2014 | 41 | 0.980 |
Why?
|
Dementia | 2 | 2023 | 187 | 0.980 |
Why?
|
Aspirin | 8 | 2022 | 155 | 0.960 |
Why?
|
Clinical Trials as Topic | 25 | 2011 | 1169 | 0.950 |
Why?
|
Gait Disorders, Neurologic | 2 | 2017 | 16 | 0.940 |
Why?
|
Cholesterol | 7 | 2011 | 356 | 0.940 |
Why?
|
Time-to-Treatment | 3 | 2015 | 98 | 0.900 |
Why?
|
Mass Screening | 5 | 2021 | 619 | 0.900 |
Why?
|
Motor Cortex | 7 | 2018 | 195 | 0.900 |
Why?
|
Seasons | 2 | 2016 | 223 | 0.900 |
Why?
|
Logistic Models | 15 | 2023 | 1185 | 0.890 |
Why?
|
Odds Ratio | 16 | 2017 | 679 | 0.850 |
Why?
|
Angioplasty | 5 | 2014 | 70 | 0.850 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 5 | 2017 | 199 | 0.840 |
Why?
|
Myocardial Infarction | 8 | 2023 | 377 | 0.840 |
Why?
|
Health Policy | 7 | 2018 | 180 | 0.830 |
Why?
|
Feeding Behavior | 3 | 2017 | 324 | 0.830 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2018 | 349 | 0.820 |
Why?
|
Virus Diseases | 1 | 2022 | 97 | 0.820 |
Why?
|
Practice Patterns, Physicians' | 12 | 2009 | 584 | 0.820 |
Why?
|
Preventive Health Services | 4 | 2012 | 37 | 0.810 |
Why?
|
Quality Indicators, Health Care | 3 | 2018 | 145 | 0.810 |
Why?
|
Time Factors | 33 | 2018 | 5215 | 0.810 |
Why?
|
Blood Pressure | 14 | 2016 | 1146 | 0.790 |
Why?
|
Uganda | 5 | 2023 | 34 | 0.780 |
Why?
|
Retrospective Studies | 31 | 2024 | 8476 | 0.780 |
Why?
|
Stents | 7 | 2014 | 377 | 0.780 |
Why?
|
Vision Disorders | 3 | 2017 | 75 | 0.770 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2020 | 56 | 0.760 |
Why?
|
Adult | 71 | 2022 | 25648 | 0.760 |
Why?
|
National Institutes of Health (U.S.) | 5 | 2015 | 122 | 0.760 |
Why?
|
Neurodevelopmental Disorders | 1 | 2021 | 36 | 0.760 |
Why?
|
Health Education | 9 | 2018 | 101 | 0.750 |
Why?
|
Decision Support Techniques | 3 | 2019 | 160 | 0.740 |
Why?
|
Financial Management | 1 | 2020 | 21 | 0.730 |
Why?
|
Diet | 4 | 2021 | 443 | 0.720 |
Why?
|
Coronary Disease | 11 | 2014 | 261 | 0.720 |
Why?
|
Medicaid | 4 | 2023 | 217 | 0.720 |
Why?
|
Models, Economic | 1 | 2020 | 60 | 0.720 |
Why?
|
Cardiovascular Agents | 1 | 2020 | 56 | 0.710 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2021 | 1374 | 0.710 |
Why?
|
Brain Injuries | 6 | 2006 | 161 | 0.710 |
Why?
|
Databases, Factual | 8 | 2016 | 816 | 0.710 |
Why?
|
Patient Discharge | 4 | 2023 | 300 | 0.710 |
Why?
|
Memory Disorders | 1 | 2020 | 69 | 0.700 |
Why?
|
Cytoprotection | 2 | 2009 | 47 | 0.700 |
Why?
|
Physicians | 8 | 2013 | 673 | 0.690 |
Why?
|
Influenza, Human | 1 | 2022 | 330 | 0.690 |
Why?
|
Intracranial Embolism | 1 | 2019 | 29 | 0.680 |
Why?
|
Motor Activity | 7 | 2006 | 327 | 0.680 |
Why?
|
Case-Control Studies | 11 | 2022 | 1809 | 0.670 |
Why?
|
Mortality | 4 | 2018 | 150 | 0.670 |
Why?
|
Disability Evaluation | 4 | 2017 | 136 | 0.670 |
Why?
|
North Carolina | 13 | 2018 | 50 | 0.670 |
Why?
|
Acute Disease | 15 | 2014 | 827 | 0.670 |
Why?
|
Heart Diseases | 3 | 2011 | 292 | 0.670 |
Why?
|
Blood Coagulation Tests | 4 | 2002 | 35 | 0.650 |
Why?
|
Certification | 4 | 2015 | 58 | 0.650 |
Why?
|
Antihypertensive Agents | 9 | 2022 | 522 | 0.640 |
Why?
|
Quality of Health Care | 6 | 2020 | 381 | 0.640 |
Why?
|
Predictive Value of Tests | 11 | 2019 | 1672 | 0.640 |
Why?
|
Physical Therapy Modalities | 1 | 2018 | 83 | 0.630 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 127 | 0.630 |
Why?
|
Diet, Sodium-Restricted | 1 | 2017 | 14 | 0.620 |
Why?
|
Memory | 1 | 2020 | 225 | 0.620 |
Why?
|
Heart Defects, Congenital | 1 | 2021 | 360 | 0.620 |
Why?
|
Health Services Needs and Demand | 2 | 2020 | 102 | 0.610 |
Why?
|
Health Care Surveys | 4 | 2010 | 278 | 0.610 |
Why?
|
Age Factors | 15 | 2012 | 1849 | 0.610 |
Why?
|
Reproducibility of Results | 15 | 2023 | 2704 | 0.600 |
Why?
|
Evidence-Based Medicine | 10 | 2014 | 429 | 0.590 |
Why?
|
Hospitals, Teaching | 2 | 2018 | 116 | 0.580 |
Why?
|
Hypolipidemic Agents | 2 | 2014 | 102 | 0.580 |
Why?
|
Rats | 30 | 2023 | 4004 | 0.580 |
Why?
|
Neuronal Plasticity | 4 | 2008 | 187 | 0.570 |
Why?
|
Prevalence | 9 | 2023 | 1240 | 0.570 |
Why?
|
Prospective Studies | 14 | 2024 | 4212 | 0.570 |
Why?
|
Dyslipidemias | 2 | 2014 | 109 | 0.560 |
Why?
|
Blood Coagulation Disorders | 3 | 2002 | 63 | 0.560 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 311 | 0.550 |
Why?
|
Choice Behavior | 1 | 2017 | 160 | 0.550 |
Why?
|
Carotid Arteries | 6 | 2014 | 127 | 0.550 |
Why?
|
Amphetamines | 7 | 2003 | 18 | 0.540 |
Why?
|
White Matter | 3 | 2023 | 80 | 0.540 |
Why?
|
Locomotion | 4 | 2006 | 131 | 0.540 |
Why?
|
Registries | 11 | 2022 | 703 | 0.530 |
Why?
|
Cerebral Revascularization | 2 | 2012 | 26 | 0.530 |
Why?
|
Neuroimaging | 2 | 2017 | 113 | 0.530 |
Why?
|
Norepinephrine | 7 | 2006 | 167 | 0.530 |
Why?
|
Computed Tomography Angiography | 1 | 2016 | 131 | 0.520 |
Why?
|
Nervous System Diseases | 3 | 2015 | 151 | 0.520 |
Why?
|
Animals | 54 | 2023 | 26706 | 0.520 |
Why?
|
Neurotransmitter Agents | 5 | 2006 | 106 | 0.520 |
Why?
|
Comorbidity | 9 | 2018 | 945 | 0.510 |
Why?
|
National Health Programs | 2 | 2011 | 20 | 0.500 |
Why?
|
Temperature | 1 | 2016 | 396 | 0.500 |
Why?
|
Homocysteine | 3 | 2011 | 29 | 0.500 |
Why?
|
Patient Care | 1 | 2015 | 100 | 0.490 |
Why?
|
Disease Management | 5 | 2011 | 328 | 0.490 |
Why?
|
Magnetic Resonance Angiography | 6 | 2011 | 262 | 0.490 |
Why?
|
Models, Statistical | 4 | 2010 | 575 | 0.490 |
Why?
|
Proportional Hazards Models | 9 | 2022 | 860 | 0.490 |
Why?
|
Risk | 13 | 2019 | 674 | 0.480 |
Why?
|
Precision Medicine | 1 | 2018 | 395 | 0.480 |
Why?
|
Estrogen Replacement Therapy | 4 | 2004 | 45 | 0.480 |
Why?
|
Clinical Competence | 3 | 2013 | 756 | 0.470 |
Why?
|
Biomarkers | 9 | 2023 | 1722 | 0.470 |
Why?
|
Cough | 4 | 2008 | 54 | 0.460 |
Why?
|
Hospitals, Veterans | 2 | 2003 | 17 | 0.460 |
Why?
|
Central Nervous System Agents | 5 | 2003 | 15 | 0.460 |
Why?
|
Prognosis | 14 | 2019 | 3681 | 0.450 |
Why?
|
Cytidine Diphosphate Choline | 1 | 2012 | 2 | 0.450 |
Why?
|
Deglutition Disorders | 4 | 2019 | 115 | 0.440 |
Why?
|
Nootropic Agents | 1 | 2012 | 10 | 0.440 |
Why?
|
Embolism | 2 | 2011 | 31 | 0.440 |
Why?
|
Kidney Diseases | 1 | 2016 | 416 | 0.440 |
Why?
|
Rural Health Services | 1 | 2012 | 13 | 0.440 |
Why?
|
Tomography, X-Ray Computed | 7 | 2015 | 2585 | 0.430 |
Why?
|
Observer Variation | 9 | 2015 | 602 | 0.420 |
Why?
|
Chi-Square Distribution | 8 | 2016 | 364 | 0.410 |
Why?
|
Ambulatory Care | 1 | 2013 | 180 | 0.410 |
Why?
|
Societies, Medical | 6 | 2018 | 573 | 0.410 |
Why?
|
Hospital Rapid Response Team | 1 | 2011 | 27 | 0.410 |
Why?
|
Movement Disorders | 4 | 2003 | 44 | 0.400 |
Why?
|
Amphetamine | 7 | 2008 | 101 | 0.400 |
Why?
|
Postural Balance | 8 | 2017 | 42 | 0.400 |
Why?
|
Health Personnel | 4 | 2010 | 201 | 0.400 |
Why?
|
Patient Selection | 7 | 2011 | 686 | 0.400 |
Why?
|
Ultrasonography, Doppler, Duplex | 5 | 2011 | 40 | 0.400 |
Why?
|
Amyloid beta-Peptides | 3 | 2023 | 203 | 0.390 |
Why?
|
Behavior, Animal | 12 | 2008 | 373 | 0.390 |
Why?
|
Organizations, Nonprofit | 1 | 2011 | 8 | 0.390 |
Why?
|
Young Adult | 9 | 2019 | 5977 | 0.390 |
Why?
|
Fee-for-Service Plans | 5 | 2022 | 30 | 0.380 |
Why?
|
Endovascular Procedures | 1 | 2014 | 218 | 0.380 |
Why?
|
Cardiomegaly | 1 | 2011 | 114 | 0.380 |
Why?
|
Patient Advocacy | 1 | 2011 | 49 | 0.380 |
Why?
|
Patient Care Planning | 1 | 2011 | 81 | 0.380 |
Why?
|
Diagnostic Tests, Routine | 2 | 2009 | 62 | 0.380 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2010 | 86 | 0.380 |
Why?
|
Recurrence | 14 | 2017 | 1139 | 0.380 |
Why?
|
Ticlopidine | 2 | 2009 | 25 | 0.370 |
Why?
|
Neuropsychological Tests | 3 | 2023 | 502 | 0.370 |
Why?
|
Cross-Sectional Studies | 7 | 2023 | 1618 | 0.370 |
Why?
|
Survivors | 4 | 2023 | 227 | 0.370 |
Why?
|
Cardiology | 2 | 2011 | 123 | 0.370 |
Why?
|
Lung Neoplasms | 1 | 2022 | 2262 | 0.370 |
Why?
|
Surveys and Questionnaires | 10 | 2017 | 2502 | 0.360 |
Why?
|
Corpus Striatum | 2 | 2009 | 86 | 0.360 |
Why?
|
Athetosis | 1 | 2009 | 5 | 0.360 |
Why?
|
Anomia | 1 | 2009 | 6 | 0.360 |
Why?
|
Hospital Units | 1 | 2010 | 30 | 0.360 |
Why?
|
Coronary Artery Disease | 2 | 2014 | 351 | 0.360 |
Why?
|
Family Practice | 3 | 2003 | 84 | 0.360 |
Why?
|
Chorea | 1 | 2009 | 13 | 0.360 |
Why?
|
Health Services for the Aged | 1 | 2009 | 27 | 0.360 |
Why?
|
Adolescent | 16 | 2022 | 8988 | 0.360 |
Why?
|
Sensation Disorders | 1 | 2009 | 23 | 0.360 |
Why?
|
Diagnostic Imaging | 4 | 2011 | 468 | 0.360 |
Why?
|
Restaurants | 1 | 2009 | 5 | 0.360 |
Why?
|
Ataxia | 1 | 2009 | 37 | 0.350 |
Why?
|
Life Style | 3 | 2021 | 189 | 0.350 |
Why?
|
Cerebral Angiography | 6 | 2002 | 196 | 0.350 |
Why?
|
Sex Characteristics | 3 | 2008 | 319 | 0.350 |
Why?
|
Heart Atria | 1 | 2011 | 253 | 0.350 |
Why?
|
Coronary Angiography | 1 | 2010 | 232 | 0.350 |
Why?
|
Intensive Care Units | 2 | 2020 | 374 | 0.350 |
Why?
|
Critical Care | 1 | 2012 | 371 | 0.340 |
Why?
|
Medication Adherence | 3 | 2020 | 129 | 0.340 |
Why?
|
Triglycerides | 6 | 2014 | 232 | 0.340 |
Why?
|
Medically Uninsured | 1 | 2009 | 58 | 0.340 |
Why?
|
Disease Models, Animal | 6 | 2019 | 2243 | 0.340 |
Why?
|
Allied Health Personnel | 1 | 2008 | 19 | 0.340 |
Why?
|
Vasculitis, Central Nervous System | 1 | 2008 | 3 | 0.330 |
Why?
|
Government Programs | 1 | 2008 | 8 | 0.330 |
Why?
|
Consumer Advocacy | 1 | 2008 | 10 | 0.330 |
Why?
|
Double-Blind Method | 8 | 2018 | 1824 | 0.320 |
Why?
|
Microvessels | 2 | 2019 | 70 | 0.320 |
Why?
|
Multivariate Analysis | 7 | 2017 | 999 | 0.310 |
Why?
|
Drug Combinations | 5 | 2020 | 224 | 0.310 |
Why?
|
Psychomotor Performance | 7 | 2008 | 493 | 0.310 |
Why?
|
Coronary Artery Bypass | 1 | 2009 | 228 | 0.310 |
Why?
|
Insecticides | 5 | 2008 | 27 | 0.300 |
Why?
|
Carotid Artery, Internal | 2 | 2006 | 69 | 0.300 |
Why?
|
Device Approval | 1 | 2007 | 13 | 0.300 |
Why?
|
Algorithms | 7 | 2019 | 1830 | 0.300 |
Why?
|
Data Collection | 7 | 2009 | 372 | 0.290 |
Why?
|
Follow-Up Studies | 15 | 2020 | 3639 | 0.290 |
Why?
|
Taurine | 2 | 2004 | 11 | 0.290 |
Why?
|
Physical Fitness | 3 | 2021 | 51 | 0.280 |
Why?
|
Enzyme Inhibitors | 1 | 2009 | 639 | 0.280 |
Why?
|
Platelet Activation | 1 | 2006 | 13 | 0.280 |
Why?
|
Research Design | 8 | 2022 | 594 | 0.280 |
Why?
|
Vasculitis | 3 | 2005 | 39 | 0.280 |
Why?
|
Dopamine Antagonists | 2 | 2003 | 35 | 0.280 |
Why?
|
Guanidines | 3 | 2002 | 31 | 0.270 |
Why?
|
Tamoxifen | 2 | 2004 | 168 | 0.270 |
Why?
|
Incidence | 7 | 2020 | 1578 | 0.270 |
Why?
|
Vertebral Artery Dissection | 1 | 2005 | 11 | 0.270 |
Why?
|
Carotid Artery, Internal, Dissection | 1 | 2005 | 18 | 0.270 |
Why?
|
Prenatal Exposure Delayed Effects | 2 | 2006 | 153 | 0.270 |
Why?
|
Larynx | 1 | 2006 | 38 | 0.270 |
Why?
|
Radiography, Thoracic | 1 | 2007 | 320 | 0.260 |
Why?
|
Rats, Sprague-Dawley | 13 | 2008 | 1222 | 0.260 |
Why?
|
Hospitals, Special | 1 | 2005 | 7 | 0.260 |
Why?
|
Foreign Bodies | 1 | 2006 | 63 | 0.260 |
Why?
|
Catheter Ablation | 2 | 2022 | 233 | 0.260 |
Why?
|
Alcohol Drinking | 3 | 2006 | 267 | 0.250 |
Why?
|
Magnetic Resonance Imaging | 14 | 2023 | 3366 | 0.250 |
Why?
|
Sex Factors | 7 | 2010 | 1053 | 0.250 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2004 | 34 | 0.250 |
Why?
|
Recombinant Proteins | 6 | 2018 | 1018 | 0.250 |
Why?
|
Meta-Analysis as Topic | 4 | 2022 | 87 | 0.250 |
Why?
|
Patient Education as Topic | 4 | 2017 | 351 | 0.250 |
Why?
|
Erythrocytes | 2 | 2019 | 255 | 0.250 |
Why?
|
Dermatan Sulfate | 3 | 2001 | 9 | 0.250 |
Why?
|
Heparitin Sulfate | 3 | 2001 | 27 | 0.240 |
Why?
|
Chlorine | 1 | 2004 | 8 | 0.240 |
Why?
|
Anion Exchange Protein 1, Erythrocyte | 1 | 2004 | 14 | 0.240 |
Why?
|
Magnesium Sulfate | 1 | 2004 | 15 | 0.240 |
Why?
|
Salicylates | 1 | 2004 | 25 | 0.240 |
Why?
|
Chondroitin Sulfates | 3 | 2001 | 43 | 0.240 |
Why?
|
Erythrocyte Membrane | 1 | 2004 | 60 | 0.240 |
Why?
|
Depression | 3 | 2024 | 472 | 0.240 |
Why?
|
Axonal Transport | 1 | 2003 | 31 | 0.240 |
Why?
|
Breast Neoplasms | 4 | 2004 | 2904 | 0.240 |
Why?
|
Diagnostic Techniques, Neurological | 1 | 2003 | 1 | 0.240 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2011 | 487 | 0.230 |
Why?
|
Program Evaluation | 2 | 2014 | 297 | 0.230 |
Why?
|
Cell Membrane Permeability | 1 | 2004 | 119 | 0.230 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2004 | 150 | 0.230 |
Why?
|
Social Marketing | 1 | 2003 | 10 | 0.230 |
Why?
|
Ezetimibe | 1 | 2023 | 35 | 0.230 |
Why?
|
Haloperidol | 3 | 2002 | 30 | 0.230 |
Why?
|
Nerve Degeneration | 1 | 2003 | 83 | 0.230 |
Why?
|
Thrombophilia | 1 | 2003 | 22 | 0.230 |
Why?
|
Sensitivity and Specificity | 6 | 2019 | 1991 | 0.230 |
Why?
|
Dementia, Vascular | 1 | 2023 | 7 | 0.220 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2003 | 143 | 0.220 |
Why?
|
Methylphenidate | 1 | 2003 | 10 | 0.220 |
Why?
|
Capillaries | 1 | 2023 | 91 | 0.220 |
Why?
|
Oocytes | 1 | 2004 | 221 | 0.220 |
Why?
|
Clozapine | 1 | 2002 | 9 | 0.220 |
Why?
|
DEET | 4 | 2004 | 6 | 0.220 |
Why?
|
Critical Pathways | 2 | 2014 | 35 | 0.220 |
Why?
|
Axons | 1 | 2003 | 175 | 0.220 |
Why?
|
Serotonin Antagonists | 1 | 2002 | 35 | 0.220 |
Why?
|
Diabetes Mellitus | 4 | 2024 | 805 | 0.220 |
Why?
|
Wounds and Injuries | 1 | 2005 | 232 | 0.220 |
Why?
|
Markov Chains | 2 | 2012 | 125 | 0.220 |
Why?
|
Speech | 2 | 2017 | 84 | 0.210 |
Why?
|
Nicotine | 7 | 2006 | 194 | 0.210 |
Why?
|
Antidepressive Agents | 5 | 2012 | 106 | 0.210 |
Why?
|
Hospital Bed Capacity | 2 | 2020 | 20 | 0.210 |
Why?
|
Canada | 3 | 2013 | 202 | 0.210 |
Why?
|
Sample Size | 1 | 2022 | 130 | 0.210 |
Why?
|
Telerehabilitation | 1 | 2022 | 1 | 0.210 |
Why?
|
Williams Syndrome | 1 | 2022 | 4 | 0.210 |
Why?
|
Ion Channels | 1 | 2004 | 246 | 0.210 |
Why?
|
Aortic Stenosis, Supravalvular | 1 | 2022 | 4 | 0.210 |
Why?
|
Transportation of Patients | 2 | 2014 | 32 | 0.210 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 2357 | 0.210 |
Why?
|
Carotid Artery Thrombosis | 1 | 2001 | 5 | 0.210 |
Why?
|
Age of Onset | 2 | 1999 | 310 | 0.210 |
Why?
|
Embolism, Air | 1 | 2022 | 23 | 0.210 |
Why?
|
Angiography | 1 | 2002 | 206 | 0.210 |
Why?
|
Preoperative Care | 2 | 2009 | 397 | 0.210 |
Why?
|
Triage | 2 | 2020 | 108 | 0.210 |
Why?
|
Air Pollution | 1 | 2023 | 68 | 0.210 |
Why?
|
Air Pollutants | 1 | 2023 | 78 | 0.200 |
Why?
|
Seizures | 1 | 2004 | 297 | 0.200 |
Why?
|
Intracranial Arteriosclerosis | 1 | 2022 | 49 | 0.200 |
Why?
|
Analysis of Variance | 6 | 2014 | 911 | 0.200 |
Why?
|
Health Services Research | 4 | 2010 | 136 | 0.200 |
Why?
|
Cholesterol, HDL | 4 | 2014 | 165 | 0.200 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2021 | 29 | 0.200 |
Why?
|
Postoperative Complications | 6 | 2018 | 2204 | 0.200 |
Why?
|
International Classification of Diseases | 2 | 2016 | 69 | 0.190 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 1999 | 157 | 0.190 |
Why?
|
Infusions, Intravenous | 4 | 2014 | 429 | 0.190 |
Why?
|
Pilot Projects | 3 | 2018 | 840 | 0.190 |
Why?
|
Metabolic Syndrome | 2 | 2013 | 142 | 0.190 |
Why?
|
Sodium | 2 | 2017 | 341 | 0.190 |
Why?
|
Health Resources | 3 | 2020 | 76 | 0.190 |
Why?
|
Biometry | 2 | 2000 | 66 | 0.190 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2021 | 80 | 0.190 |
Why?
|
Anticonvulsants | 4 | 2004 | 126 | 0.190 |
Why?
|
Vaccination | 1 | 2022 | 256 | 0.190 |
Why?
|
Drug Therapy, Combination | 8 | 2014 | 895 | 0.190 |
Why?
|
Central Nervous System | 3 | 1999 | 151 | 0.180 |
Why?
|
Epilepsy | 1 | 2004 | 397 | 0.180 |
Why?
|
Cholinesterase Inhibitors | 3 | 2006 | 45 | 0.180 |
Why?
|
Cannabis | 2 | 2019 | 33 | 0.180 |
Why?
|
Quality of Life | 6 | 2022 | 1587 | 0.180 |
Why?
|
Intracranial Thrombosis | 2 | 2010 | 27 | 0.180 |
Why?
|
Hospitals, Community | 2 | 2014 | 32 | 0.180 |
Why?
|
Water Pipe Smoking | 1 | 2019 | 1 | 0.180 |
Why?
|
Vascular Diseases | 2 | 2014 | 119 | 0.170 |
Why?
|
Socioeconomic Factors | 4 | 2018 | 567 | 0.170 |
Why?
|
Expert Testimony | 4 | 2004 | 46 | 0.170 |
Why?
|
Social Class | 2 | 2014 | 128 | 0.170 |
Why?
|
Diabetes Complications | 4 | 2008 | 207 | 0.170 |
Why?
|
Arm | 2 | 2017 | 91 | 0.170 |
Why?
|
Rural Population | 3 | 2022 | 136 | 0.170 |
Why?
|
Diabetic Angiopathies | 1 | 2019 | 63 | 0.170 |
Why?
|
Apolipoproteins E | 1 | 2000 | 129 | 0.170 |
Why?
|
Brain Injury, Chronic | 1 | 1999 | 9 | 0.170 |
Why?
|
Hospitals, Rural | 1 | 2018 | 5 | 0.170 |
Why?
|
Hospitals, Private | 1 | 2018 | 4 | 0.170 |
Why?
|
Plasminogen Activators | 1 | 1998 | 11 | 0.170 |
Why?
|
Hospitals, Low-Volume | 1 | 2018 | 18 | 0.170 |
Why?
|
Diagnosis-Related Groups | 1 | 1998 | 20 | 0.160 |
Why?
|
Drug Utilization | 3 | 2010 | 65 | 0.160 |
Why?
|
Accelerometry | 1 | 2019 | 36 | 0.160 |
Why?
|
Pyridostigmine Bromide | 3 | 2004 | 11 | 0.160 |
Why?
|
Hospitals, High-Volume | 1 | 2018 | 35 | 0.160 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2018 | 21 | 0.160 |
Why?
|
Diagnosis, Differential | 3 | 2016 | 1564 | 0.160 |
Why?
|
Guidelines as Topic | 3 | 2010 | 162 | 0.160 |
Why?
|
Chloride Channels | 1 | 1998 | 42 | 0.160 |
Why?
|
Patient Compliance | 3 | 2017 | 228 | 0.160 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1999 | 113 | 0.160 |
Why?
|
Neurologists | 1 | 2018 | 6 | 0.160 |
Why?
|
Movement | 5 | 2002 | 299 | 0.160 |
Why?
|
Antidotes | 1 | 2018 | 23 | 0.160 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2001 | 333 | 0.160 |
Why?
|
Emigrants and Immigrants | 1 | 2018 | 44 | 0.160 |
Why?
|
Neopterin | 1 | 2017 | 2 | 0.160 |
Why?
|
Chlorides | 1 | 1998 | 103 | 0.160 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2008 | 1960 | 0.160 |
Why?
|
Hormone Replacement Therapy | 3 | 2006 | 77 | 0.160 |
Why?
|
Peroxidase | 1 | 2017 | 51 | 0.160 |
Why?
|
Complex Mixtures | 1 | 2017 | 6 | 0.160 |
Why?
|
Nutritive Value | 1 | 2017 | 5 | 0.150 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2019 | 201 | 0.150 |
Why?
|
Cultural Characteristics | 1 | 2017 | 19 | 0.150 |
Why?
|
Osteopontin | 1 | 2017 | 47 | 0.150 |
Why?
|
Food Labeling | 1 | 2017 | 8 | 0.150 |
Why?
|
Atherosclerosis | 2 | 2013 | 245 | 0.150 |
Why?
|
Leukoencephalopathies | 1 | 2017 | 15 | 0.150 |
Why?
|
Primary Health Care | 2 | 1998 | 339 | 0.150 |
Why?
|
Temporomandibular Joint Dysfunction Syndrome | 1 | 1997 | 1 | 0.150 |
Why?
|
Tongue Habits | 1 | 1997 | 1 | 0.150 |
Why?
|
Endarterectomy | 1 | 1997 | 20 | 0.150 |
Why?
|
Neck Muscles | 1 | 1997 | 16 | 0.150 |
Why?
|
Food | 2 | 2009 | 86 | 0.150 |
Why?
|
Advisory Committees | 2 | 2010 | 90 | 0.150 |
Why?
|
Linear Models | 3 | 2014 | 421 | 0.150 |
Why?
|
Permethrin | 4 | 2004 | 9 | 0.150 |
Why?
|
Focus Groups | 1 | 2017 | 155 | 0.150 |
Why?
|
Comprehension | 1 | 2017 | 79 | 0.150 |
Why?
|
Internal Medicine | 1 | 2000 | 349 | 0.140 |
Why?
|
Data Interpretation, Statistical | 2 | 2008 | 297 | 0.140 |
Why?
|
Neoplasms, Second Primary | 1 | 1999 | 252 | 0.140 |
Why?
|
Food Preferences | 1 | 2016 | 26 | 0.140 |
Why?
|
Length of Stay | 3 | 2009 | 704 | 0.140 |
Why?
|
Functional Laterality | 3 | 2001 | 201 | 0.140 |
Why?
|
Healthcare Disparities | 2 | 2011 | 372 | 0.140 |
Why?
|
Eye | 1 | 2017 | 111 | 0.140 |
Why?
|
Psychotropic Drugs | 1 | 1997 | 75 | 0.140 |
Why?
|
Tertiary Care Centers | 2 | 2016 | 94 | 0.140 |
Why?
|
Hepatitis B | 2 | 2011 | 74 | 0.140 |
Why?
|
Qualitative Research | 1 | 2017 | 256 | 0.140 |
Why?
|
Survival Analysis | 5 | 2009 | 1540 | 0.140 |
Why?
|
Ethics, Medical | 4 | 2020 | 306 | 0.140 |
Why?
|
Psychotherapy, Group | 1 | 2016 | 33 | 0.140 |
Why?
|
Troponin | 1 | 2016 | 24 | 0.140 |
Why?
|
Face | 1 | 2017 | 114 | 0.140 |
Why?
|
Echocardiography, Transesophageal | 4 | 2011 | 344 | 0.140 |
Why?
|
Cost-Benefit Analysis | 3 | 2014 | 453 | 0.140 |
Why?
|
Evidence-Based Practice | 1 | 2016 | 45 | 0.140 |
Why?
|
Policy Making | 1 | 2016 | 62 | 0.140 |
Why?
|
Obesity | 5 | 2018 | 964 | 0.140 |
Why?
|
Stroke, Lacunar | 1 | 2015 | 4 | 0.140 |
Why?
|
Urban Population | 2 | 2022 | 214 | 0.140 |
Why?
|
Lipoproteins, HDL | 2 | 2013 | 96 | 0.140 |
Why?
|
Liver Transplantation | 5 | 2011 | 1271 | 0.140 |
Why?
|
Causality | 2 | 2009 | 81 | 0.130 |
Why?
|
Carcinoma | 1 | 1999 | 436 | 0.130 |
Why?
|
Peptide Fragments | 1 | 2018 | 462 | 0.130 |
Why?
|
Acetylcholinesterase | 6 | 2008 | 47 | 0.130 |
Why?
|
Potassium | 2 | 2003 | 281 | 0.130 |
Why?
|
Pancreas | 3 | 2023 | 239 | 0.130 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 2 | 1995 | 87 | 0.130 |
Why?
|
Reaction Time | 1 | 2017 | 310 | 0.130 |
Why?
|
Renal Dialysis | 1 | 2018 | 355 | 0.130 |
Why?
|
Eating | 1 | 2016 | 166 | 0.130 |
Why?
|
Attitude | 1 | 2016 | 127 | 0.130 |
Why?
|
Myocardium | 1 | 1998 | 550 | 0.130 |
Why?
|
Fibromuscular Dysplasia | 2 | 1995 | 11 | 0.130 |
Why?
|
Clinical Protocols | 3 | 2014 | 156 | 0.130 |
Why?
|
Mental Disorders | 1 | 1998 | 371 | 0.130 |
Why?
|
Clinical Decision-Making | 1 | 2017 | 257 | 0.130 |
Why?
|
Nerve Regeneration | 2 | 1997 | 32 | 0.130 |
Why?
|
Sympathomimetics | 3 | 2006 | 12 | 0.130 |
Why?
|
Craniocerebral Trauma | 1 | 1995 | 52 | 0.130 |
Why?
|
Chlorpyrifos | 2 | 2006 | 4 | 0.130 |
Why?
|
Blood Platelet Disorders | 1 | 2014 | 9 | 0.130 |
Why?
|
Insurance Claim Review | 1 | 2015 | 41 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 315 | 0.130 |
Why?
|
Coronavirus Infections | 1 | 2020 | 300 | 0.130 |
Why?
|
Regional Health Planning | 1 | 2014 | 13 | 0.130 |
Why?
|
Geographic Information Systems | 1 | 2014 | 20 | 0.130 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 1686 | 0.130 |
Why?
|
WT1 Proteins | 1 | 2014 | 19 | 0.130 |
Why?
|
Education, Medical, Continuing | 3 | 2010 | 107 | 0.130 |
Why?
|
Motor Skills | 2 | 2017 | 71 | 0.120 |
Why?
|
Motivation | 1 | 2017 | 287 | 0.120 |
Why?
|
Renal Replacement Therapy | 1 | 2014 | 30 | 0.120 |
Why?
|
RNA, Neoplasm | 1 | 2014 | 87 | 0.120 |
Why?
|
Survival Rate | 3 | 2012 | 1864 | 0.120 |
Why?
|
Warfarin | 3 | 2001 | 103 | 0.120 |
Why?
|
Teaching | 1 | 2015 | 147 | 0.120 |
Why?
|
Sequence Homology | 1 | 1994 | 28 | 0.120 |
Why?
|
United States Agency for Healthcare Research and Quality | 1 | 2013 | 6 | 0.120 |
Why?
|
Health Status Disparities | 1 | 2016 | 170 | 0.120 |
Why?
|
Electroencephalography | 15 | 1973 | 709 | 0.120 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2007 | 231 | 0.120 |
Why?
|
Cost of Illness | 2 | 2008 | 150 | 0.120 |
Why?
|
Smoking | 4 | 2018 | 609 | 0.120 |
Why?
|
Niacin | 1 | 2013 | 37 | 0.110 |
Why?
|
Foramen Ovale, Patent | 1 | 2013 | 18 | 0.110 |
Why?
|
Physical Examination | 1 | 1994 | 149 | 0.110 |
Why?
|
Neurotoxicity Syndromes | 2 | 2004 | 28 | 0.110 |
Why?
|
Sequence Alignment | 1 | 1994 | 352 | 0.110 |
Why?
|
Insect Repellents | 2 | 2004 | 3 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 1 | 1999 | 1313 | 0.110 |
Why?
|
Models, Theoretical | 2 | 2015 | 482 | 0.110 |
Why?
|
Cerebral Cortex | 9 | 2002 | 586 | 0.110 |
Why?
|
Hepatitis B virus | 2 | 2011 | 43 | 0.110 |
Why?
|
Residence Characteristics | 1 | 2014 | 197 | 0.110 |
Why?
|
Dizocilpine Maleate | 1 | 1992 | 12 | 0.110 |
Why?
|
Clinical Coding | 1 | 2012 | 23 | 0.110 |
Why?
|
Cognition Disorders | 2 | 2014 | 236 | 0.110 |
Why?
|
Deglutition | 2 | 2019 | 73 | 0.110 |
Why?
|
Inflammation | 4 | 2023 | 926 | 0.110 |
Why?
|
Leukemia | 1 | 2014 | 320 | 0.110 |
Why?
|
Guideline Adherence | 1 | 2014 | 224 | 0.110 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 1993 | 155 | 0.110 |
Why?
|
Thrombectomy | 2 | 2018 | 158 | 0.100 |
Why?
|
Patient Care Team | 1 | 2014 | 280 | 0.100 |
Why?
|
Antioxidants | 2 | 2004 | 223 | 0.100 |
Why?
|
Aging | 2 | 2021 | 693 | 0.100 |
Why?
|
Multicenter Studies as Topic | 4 | 2009 | 159 | 0.100 |
Why?
|
United States Department of Veterans Affairs | 2 | 2003 | 26 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 3 | 2010 | 2272 | 0.100 |
Why?
|
Medical Records | 3 | 2016 | 119 | 0.100 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2011 | 24 | 0.100 |
Why?
|
Quality Improvement | 2 | 2014 | 427 | 0.100 |
Why?
|
Injections, Intravenous | 3 | 2009 | 242 | 0.100 |
Why?
|
Voluntary Health Agencies | 1 | 2011 | 5 | 0.100 |
Why?
|
Pyrethrins | 2 | 2001 | 10 | 0.100 |
Why?
|
GABA Agents | 2 | 2003 | 8 | 0.100 |
Why?
|
Muscle Spasticity | 1 | 2011 | 9 | 0.100 |
Why?
|
Lobbying | 1 | 2011 | 3 | 0.100 |
Why?
|
Adrenergic alpha-Antagonists | 2 | 2003 | 35 | 0.100 |
Why?
|
Adrenergic alpha-Agonists | 2 | 2003 | 34 | 0.100 |
Why?
|
Cryosurgery | 1 | 2011 | 41 | 0.100 |
Why?
|
Nucleosides | 1 | 2011 | 22 | 0.100 |
Why?
|
Hyperhomocysteinemia | 2 | 2001 | 11 | 0.100 |
Why?
|
Phenotype | 2 | 2010 | 2389 | 0.100 |
Why?
|
Myelodysplastic Syndromes | 1 | 2014 | 346 | 0.100 |
Why?
|
Neuromuscular Diseases | 1 | 2011 | 30 | 0.100 |
Why?
|
Smoking Cessation | 2 | 2019 | 230 | 0.100 |
Why?
|
Attention | 3 | 1991 | 389 | 0.100 |
Why?
|
Contraceptives, Oral | 2 | 2001 | 46 | 0.100 |
Why?
|
Receptors, Nicotinic | 4 | 2008 | 129 | 0.100 |
Why?
|
Lipoproteins | 1 | 2011 | 136 | 0.090 |
Why?
|
Databases as Topic | 1 | 2010 | 92 | 0.090 |
Why?
|
Nucleotides | 1 | 2011 | 95 | 0.090 |
Why?
|
Nutritional Status | 2 | 2001 | 83 | 0.090 |
Why?
|
Rats, Inbred Strains | 4 | 1992 | 312 | 0.090 |
Why?
|
Nerve Fibers, Myelinated | 1 | 2010 | 31 | 0.090 |
Why?
|
Forecasting | 2 | 2010 | 305 | 0.090 |
Why?
|
Electric Fish | 1 | 1990 | 18 | 0.090 |
Why?
|
Thrombosis | 1 | 2013 | 296 | 0.090 |
Why?
|
Health Priorities | 1 | 2010 | 23 | 0.090 |
Why?
|
Thromboembolism | 1 | 2011 | 119 | 0.090 |
Why?
|
C-Reactive Protein | 1 | 2011 | 190 | 0.090 |
Why?
|
Cerebrovascular Circulation | 2 | 2006 | 212 | 0.090 |
Why?
|
Clonidine | 1 | 1990 | 37 | 0.090 |
Why?
|
Drug Interactions | 5 | 2019 | 248 | 0.090 |
Why?
|
Health Status | 4 | 2017 | 360 | 0.090 |
Why?
|
Venous Thrombosis | 2 | 2010 | 243 | 0.090 |
Why?
|
Vitamin K | 1 | 2009 | 25 | 0.090 |
Why?
|
Bias | 2 | 2000 | 127 | 0.090 |
Why?
|
Community Health Planning | 2 | 2014 | 21 | 0.090 |
Why?
|
Latin America | 1 | 2009 | 14 | 0.090 |
Why?
|
Amyloid | 2 | 2020 | 85 | 0.090 |
Why?
|
Risk Reduction Behavior | 3 | 2006 | 98 | 0.090 |
Why?
|
Hemorrhage | 3 | 2009 | 267 | 0.090 |
Why?
|
Domestic Violence | 1 | 2009 | 24 | 0.090 |
Why?
|
Telephone | 1 | 2009 | 32 | 0.090 |
Why?
|
Computer Simulation | 1 | 1994 | 1079 | 0.090 |
Why?
|
Professional Practice | 3 | 2004 | 46 | 0.080 |
Why?
|
Kidney | 4 | 2019 | 1245 | 0.080 |
Why?
|
Physical Conditioning, Animal | 1 | 2008 | 19 | 0.080 |
Why?
|
Quality Assurance, Health Care | 2 | 2002 | 219 | 0.080 |
Why?
|
Anemia, Sickle Cell | 2 | 2001 | 131 | 0.080 |
Why?
|
Genetic Association Studies | 1 | 2010 | 294 | 0.080 |
Why?
|
Pneumonia, Aspiration | 1 | 2008 | 19 | 0.080 |
Why?
|
Global Health | 1 | 2010 | 193 | 0.080 |
Why?
|
Gene Frequency | 1 | 2010 | 677 | 0.080 |
Why?
|
Vascular Surgical Procedures | 1 | 2010 | 148 | 0.080 |
Why?
|
RNA, Messenger | 1 | 2014 | 1988 | 0.080 |
Why?
|
Nitro Compounds | 1 | 2008 | 2 | 0.080 |
Why?
|
Lip | 1 | 1988 | 16 | 0.080 |
Why?
|
Phonetics | 1 | 1988 | 36 | 0.080 |
Why?
|
ROC Curve | 2 | 2017 | 752 | 0.080 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2008 | 58 | 0.080 |
Why?
|
Apolipoprotein A-I | 1 | 2008 | 71 | 0.080 |
Why?
|
Disease Progression | 2 | 2010 | 1534 | 0.080 |
Why?
|
Research | 1 | 2009 | 253 | 0.080 |
Why?
|
Lipids | 2 | 2007 | 270 | 0.080 |
Why?
|
Referral and Consultation | 2 | 2003 | 328 | 0.080 |
Why?
|
Tongue | 1 | 1988 | 57 | 0.080 |
Why?
|
Language | 1 | 2009 | 151 | 0.080 |
Why?
|
Butyrylcholinesterase | 5 | 2008 | 10 | 0.080 |
Why?
|
Likelihood Functions | 2 | 2006 | 251 | 0.080 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2014 | 878 | 0.080 |
Why?
|
Infusions, Intra-Arterial | 2 | 2011 | 34 | 0.080 |
Why?
|
Health Care Rationing | 2 | 2020 | 83 | 0.080 |
Why?
|
Health Care Reform | 1 | 2008 | 90 | 0.070 |
Why?
|
Reticular Formation | 4 | 1975 | 17 | 0.070 |
Why?
|
United Kingdom | 2 | 2017 | 164 | 0.070 |
Why?
|
Intraoperative Complications | 2 | 1999 | 185 | 0.070 |
Why?
|
Receptors, Muscarinic | 5 | 2008 | 49 | 0.070 |
Why?
|
Imidazoles | 1 | 2008 | 162 | 0.070 |
Why?
|
Hyperlipidemias | 2 | 2008 | 95 | 0.070 |
Why?
|
Substance-Related Disorders | 2 | 2001 | 394 | 0.070 |
Why?
|
Confidence Intervals | 2 | 2011 | 229 | 0.070 |
Why?
|
RNA | 1 | 2010 | 561 | 0.070 |
Why?
|
Regression Analysis | 3 | 2010 | 596 | 0.070 |
Why?
|
P-Selectin | 1 | 2006 | 13 | 0.070 |
Why?
|
Biomarkers, Tumor | 1 | 2014 | 1464 | 0.070 |
Why?
|
Telemedicine | 2 | 2020 | 168 | 0.070 |
Why?
|
Educational Status | 2 | 2005 | 190 | 0.070 |
Why?
|
Health Behavior | 3 | 2018 | 183 | 0.070 |
Why?
|
Biopsy | 2 | 2008 | 1163 | 0.070 |
Why?
|
Longitudinal Studies | 3 | 2017 | 1019 | 0.070 |
Why?
|
Benchmarking | 2 | 2023 | 78 | 0.070 |
Why?
|
Moyamoya Disease | 1 | 2005 | 14 | 0.070 |
Why?
|
Maternal Exposure | 1 | 2006 | 57 | 0.070 |
Why?
|
Hippocampus | 5 | 1990 | 442 | 0.070 |
Why?
|
Women's Health | 1 | 2006 | 100 | 0.070 |
Why?
|
Estrogens, Conjugated (USP) | 2 | 2004 | 16 | 0.070 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2005 | 46 | 0.070 |
Why?
|
Acetaminophen | 1 | 2005 | 54 | 0.070 |
Why?
|
Health Planning Guidelines | 1 | 2005 | 24 | 0.070 |
Why?
|
Purkinje Cells | 1 | 2006 | 80 | 0.070 |
Why?
|
Models, Genetic | 1 | 2010 | 929 | 0.070 |
Why?
|
Hypotonic Solutions | 2 | 1998 | 8 | 0.070 |
Why?
|
Placebos | 9 | 2009 | 218 | 0.070 |
Why?
|
Sympatholytics | 3 | 1997 | 6 | 0.060 |
Why?
|
Cardiovascular System | 1 | 2005 | 71 | 0.060 |
Why?
|
Subarachnoid Hemorrhage | 1 | 2006 | 137 | 0.060 |
Why?
|
Ethics, Professional | 1 | 2004 | 10 | 0.060 |
Why?
|
Osmolar Concentration | 2 | 1998 | 181 | 0.060 |
Why?
|
Pandemics | 2 | 2022 | 737 | 0.060 |
Why?
|
Illusions | 1 | 2004 | 12 | 0.060 |
Why?
|
Retinal Artery Occlusion | 1 | 2004 | 12 | 0.060 |
Why?
|
Administration, Oral | 4 | 2012 | 683 | 0.060 |
Why?
|
Trout | 1 | 2004 | 2 | 0.060 |
Why?
|
Malathion | 1 | 2004 | 1 | 0.060 |
Why?
|
Anti-Anxiety Agents | 2 | 2000 | 23 | 0.060 |
Why?
|
Rubidium | 1 | 2004 | 9 | 0.060 |
Why?
|
Water-Electrolyte Balance | 1 | 2004 | 66 | 0.060 |
Why?
|
Biological Transport | 2 | 1998 | 396 | 0.060 |
Why?
|
Alaska | 1 | 2023 | 17 | 0.060 |
Why?
|
Speech Therapy | 1 | 2003 | 8 | 0.060 |
Why?
|
Emergency Medical Technicians | 1 | 2003 | 14 | 0.060 |
Why?
|
Endocarditis | 1 | 2003 | 18 | 0.060 |
Why?
|
Military Personnel | 1 | 2005 | 85 | 0.060 |
Why?
|
Xenopus laevis | 1 | 2004 | 137 | 0.060 |
Why?
|
Excitatory Amino Acid Antagonists | 2 | 2001 | 78 | 0.060 |
Why?
|
Occupational Therapy | 1 | 2003 | 16 | 0.060 |
Why?
|
Wales | 1 | 2003 | 10 | 0.060 |
Why?
|
Television | 1 | 2003 | 29 | 0.060 |
Why?
|
Microcirculation | 2 | 2019 | 106 | 0.060 |
Why?
|
England | 1 | 2003 | 41 | 0.060 |
Why?
|
Rats, Transgenic | 1 | 2023 | 6 | 0.060 |
Why?
|
Mass Media | 1 | 2003 | 26 | 0.060 |
Why?
|
Infant, Low Birth Weight | 1 | 2003 | 58 | 0.060 |
Why?
|
Therapeutics | 1 | 2003 | 12 | 0.060 |
Why?
|
Tranquilizing Agents | 5 | 1973 | 7 | 0.060 |
Why?
|
Nitrogen Dioxide | 1 | 2023 | 11 | 0.060 |
Why?
|
Pregnancy | 3 | 2008 | 2901 | 0.060 |
Why?
|
Europe | 1 | 2004 | 309 | 0.060 |
Why?
|
Amyloidogenic Proteins | 1 | 2023 | 13 | 0.060 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2003 | 24 | 0.060 |
Why?
|
Cloning, Molecular | 1 | 2004 | 646 | 0.060 |
Why?
|
Vegetables | 1 | 2003 | 45 | 0.060 |
Why?
|
Denmark | 1 | 2022 | 15 | 0.050 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2023 | 58 | 0.050 |
Why?
|
Heart Valve Diseases | 1 | 2003 | 113 | 0.050 |
Why?
|
Fruit | 1 | 2003 | 75 | 0.050 |
Why?
|
Benzodiazepines | 1 | 2003 | 65 | 0.050 |
Why?
|
Receptor, Muscarinic M2 | 4 | 2003 | 11 | 0.050 |
Why?
|
Sarin | 1 | 2002 | 2 | 0.050 |
Why?
|
Aftercare | 1 | 2023 | 85 | 0.050 |
Why?
|
Hematoma | 1 | 2023 | 104 | 0.050 |
Why?
|
Nutrition Surveys | 1 | 2003 | 114 | 0.050 |
Why?
|
Models, Animal | 1 | 2003 | 264 | 0.050 |
Why?
|
Autoimmune Diseases | 1 | 2004 | 241 | 0.050 |
Why?
|
Particulate Matter | 1 | 2023 | 79 | 0.050 |
Why?
|
Species Specificity | 1 | 2004 | 678 | 0.050 |
Why?
|
Brain Chemistry | 1 | 2002 | 121 | 0.050 |
Why?
|
Dietary Supplements | 1 | 2003 | 128 | 0.050 |
Why?
|
Body Weight | 2 | 2004 | 458 | 0.050 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2023 | 168 | 0.050 |
Why?
|
Collagen | 1 | 2023 | 273 | 0.050 |
Why?
|
Bacteroides Infections | 1 | 2001 | 8 | 0.050 |
Why?
|
Heart Rate | 2 | 2023 | 493 | 0.050 |
Why?
|
Aortic Valve | 1 | 2003 | 230 | 0.050 |
Why?
|
Metronidazole | 1 | 2001 | 26 | 0.050 |
Why?
|
Mitral Valve | 1 | 2003 | 253 | 0.050 |
Why?
|
Ethics Committees, Research | 1 | 2021 | 33 | 0.050 |
Why?
|
Attitude of Health Personnel | 2 | 2018 | 636 | 0.050 |
Why?
|
Research Personnel | 2 | 2004 | 67 | 0.050 |
Why?
|
Radiography | 1 | 2003 | 808 | 0.050 |
Why?
|
Patient Reported Outcome Measures | 1 | 2022 | 164 | 0.050 |
Why?
|
Endocarditis, Bacterial | 1 | 2001 | 33 | 0.050 |
Why?
|
Organometallic Compounds | 1 | 2002 | 132 | 0.050 |
Why?
|
Methaqualone | 2 | 1971 | 2 | 0.050 |
Why?
|
Glutethimide | 2 | 1971 | 3 | 0.050 |
Why?
|
Catheterization | 1 | 2002 | 232 | 0.050 |
Why?
|
Safety | 1 | 2002 | 152 | 0.050 |
Why?
|
Bacteroides fragilis | 1 | 2001 | 42 | 0.050 |
Why?
|
Medical Records Systems, Computerized | 1 | 2001 | 40 | 0.050 |
Why?
|
Trauma Centers | 1 | 2002 | 115 | 0.050 |
Why?
|
Sex Distribution | 2 | 1998 | 173 | 0.050 |
Why?
|
Inhalation | 1 | 2001 | 31 | 0.050 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2021 | 41 | 0.050 |
Why?
|
Lamivudine | 1 | 2000 | 13 | 0.050 |
Why?
|
Arteries | 1 | 2022 | 177 | 0.050 |
Why?
|
Physician's Role | 2 | 2018 | 179 | 0.050 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2000 | 23 | 0.050 |
Why?
|
Blood-Brain Barrier | 1 | 2001 | 70 | 0.050 |
Why?
|
Nitric Oxide | 1 | 2002 | 279 | 0.050 |
Why?
|
Immunization, Passive | 1 | 2000 | 72 | 0.050 |
Why?
|
Disclosure | 1 | 2021 | 108 | 0.050 |
Why?
|
Sleep Initiation and Maintenance Disorders | 2 | 1971 | 50 | 0.050 |
Why?
|
Testis | 1 | 2001 | 152 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2023 | 296 | 0.050 |
Why?
|
Total Quality Management | 1 | 2000 | 33 | 0.050 |
Why?
|
Estradiol | 1 | 2001 | 252 | 0.050 |
Why?
|
Finland | 1 | 1999 | 29 | 0.050 |
Why?
|
Immunoglobulins | 1 | 2000 | 148 | 0.050 |
Why?
|
Transplantation, Homologous | 2 | 2000 | 996 | 0.040 |
Why?
|
Hypnotics and Sedatives | 5 | 1973 | 127 | 0.040 |
Why?
|
Drug Prescriptions | 2 | 2005 | 141 | 0.040 |
Why?
|
Eicosanoids | 1 | 2019 | 16 | 0.040 |
Why?
|
Consensus | 1 | 2021 | 336 | 0.040 |
Why?
|
Nuclear Family | 1 | 1999 | 92 | 0.040 |
Why?
|
Glycosaminoglycans | 2 | 1990 | 47 | 0.040 |
Why?
|
Administration, Topical | 3 | 2006 | 95 | 0.040 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2000 | 83 | 0.040 |
Why?
|
Diseases in Twins | 1 | 1999 | 65 | 0.040 |
Why?
|
Erythropoiesis | 1 | 2019 | 52 | 0.040 |
Why?
|
Infant | 2 | 2023 | 3048 | 0.040 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2001 | 183 | 0.040 |
Why?
|
Erythropoietin | 1 | 2019 | 91 | 0.040 |
Why?
|
Liver | 3 | 2019 | 1229 | 0.040 |
Why?
|
Cineradiography | 1 | 2019 | 24 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2023 | 1557 | 0.040 |
Why?
|
Sampling Studies | 2 | 2000 | 70 | 0.040 |
Why?
|
Cerebral Arteries | 1 | 1999 | 74 | 0.040 |
Why?
|
Carcinoma in Situ | 1 | 1999 | 53 | 0.040 |
Why?
|
Discriminant Analysis | 1 | 2019 | 66 | 0.040 |
Why?
|
Axilla | 1 | 1999 | 99 | 0.040 |
Why?
|
Rhabdomyolysis | 1 | 2019 | 28 | 0.040 |
Why?
|
Intracranial Embolism and Thrombosis | 1 | 1998 | 14 | 0.040 |
Why?
|
Cultural Competency | 1 | 2018 | 21 | 0.040 |
Why?
|
Insurance Benefits | 1 | 2018 | 8 | 0.040 |
Why?
|
Antipsychotic Agents | 1 | 2000 | 123 | 0.040 |
Why?
|
Muscular Diseases | 1 | 2019 | 63 | 0.040 |
Why?
|
Carcinoma, Lobular | 1 | 1999 | 81 | 0.040 |
Why?
|
Cell Size | 1 | 1998 | 66 | 0.040 |
Why?
|
Child | 4 | 2006 | 6933 | 0.040 |
Why?
|
Factor Xa | 1 | 2018 | 4 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 1999 | 162 | 0.040 |
Why?
|
Cytosol | 1 | 1998 | 190 | 0.040 |
Why?
|
Mice | 3 | 2023 | 11439 | 0.040 |
Why?
|
Oxidopamine | 1 | 1997 | 8 | 0.040 |
Why?
|
Dopamine Agents | 1 | 1998 | 29 | 0.040 |
Why?
|
Upper Extremity | 1 | 2018 | 50 | 0.040 |
Why?
|
Arginine | 1 | 2018 | 136 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2010 | 1205 | 0.040 |
Why?
|
Rats, Mutant Strains | 1 | 2017 | 23 | 0.040 |
Why?
|
Muscles | 2 | 1995 | 194 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 1 | 1999 | 468 | 0.040 |
Why?
|
Maze Learning | 1 | 2017 | 28 | 0.040 |
Why?
|
Lymph Node Excision | 1 | 1999 | 217 | 0.040 |
Why?
|
Cause of Death | 2 | 2000 | 277 | 0.040 |
Why?
|
Health Surveys | 1 | 1998 | 239 | 0.040 |
Why?
|
Diplopia | 1 | 2017 | 13 | 0.040 |
Why?
|
Nerve Fibers | 1 | 1997 | 46 | 0.040 |
Why?
|
Job Satisfaction | 1 | 2018 | 73 | 0.040 |
Why?
|
Apolipoprotein E4 | 1 | 2017 | 27 | 0.040 |
Why?
|
Cyclic AMP | 1 | 1998 | 274 | 0.040 |
Why?
|
Geriatric Assessment | 1 | 2019 | 166 | 0.040 |
Why?
|
Cell Count | 1 | 1997 | 197 | 0.040 |
Why?
|
Endothelium | 1 | 2017 | 59 | 0.040 |
Why?
|
Echocardiography | 2 | 2009 | 914 | 0.040 |
Why?
|
Gene Knockout Techniques | 1 | 2017 | 77 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2003 | 2380 | 0.040 |
Why?
|
Israel | 3 | 2005 | 55 | 0.040 |
Why?
|
Coccidioidomycosis | 1 | 1997 | 7 | 0.040 |
Why?
|
Knowledge | 1 | 1997 | 29 | 0.040 |
Why?
|
Intestines | 1 | 2000 | 411 | 0.040 |
Why?
|
Psychometrics | 1 | 1998 | 327 | 0.040 |
Why?
|
Consciousness Disorders | 1 | 1997 | 9 | 0.040 |
Why?
|
Attitude to Health | 1 | 1998 | 220 | 0.040 |
Why?
|
Videotape Recording | 1 | 1997 | 47 | 0.040 |
Why?
|
Animals, Newborn | 1 | 1998 | 516 | 0.040 |
Why?
|
Betacoronavirus | 1 | 2020 | 257 | 0.040 |
Why?
|
Drug Synergism | 1 | 2017 | 303 | 0.040 |
Why?
|
Electromyography | 1 | 1997 | 184 | 0.040 |
Why?
|
In Vitro Techniques | 1 | 1998 | 990 | 0.040 |
Why?
|
Brain Mapping | 2 | 2010 | 552 | 0.040 |
Why?
|
Awareness | 1 | 1997 | 93 | 0.040 |
Why?
|
Piperazines | 1 | 2018 | 272 | 0.040 |
Why?
|
Research Support as Topic | 2 | 2008 | 80 | 0.040 |
Why?
|
Tight Junctions | 1 | 2017 | 149 | 0.030 |
Why?
|
Multiple Sclerosis | 1 | 1998 | 262 | 0.030 |
Why?
|
Muscle Contraction | 1 | 1997 | 284 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2001 | 747 | 0.030 |
Why?
|
Neurosurgery | 1 | 1997 | 84 | 0.030 |
Why?
|
Nausea | 1 | 2017 | 175 | 0.030 |
Why?
|
Gene Products, tat | 1 | 2015 | 7 | 0.030 |
Why?
|
Patient Admission | 1 | 2016 | 112 | 0.030 |
Why?
|
Electrocardiography, Ambulatory | 1 | 1995 | 27 | 0.030 |
Why?
|
Tobacco Products | 1 | 2016 | 41 | 0.030 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2015 | 35 | 0.030 |
Why?
|
Pipecolic Acids | 1 | 1995 | 14 | 0.030 |
Why?
|
Reflex | 3 | 2002 | 79 | 0.030 |
Why?
|
Gene Expression | 1 | 2000 | 1286 | 0.030 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 1 | 1995 | 40 | 0.030 |
Why?
|
Hypertension, Portal | 1 | 1995 | 47 | 0.030 |
Why?
|
Suction | 1 | 1995 | 35 | 0.030 |
Why?
|
Tomography, Emission-Computed | 1 | 1995 | 102 | 0.030 |
Why?
|
Actins | 1 | 1998 | 451 | 0.030 |
Why?
|
Chlordiazepoxide | 4 | 1971 | 4 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2000 | 1944 | 0.030 |
Why?
|
Cholinesterases | 2 | 2006 | 17 | 0.030 |
Why?
|
Ethanol | 2 | 1969 | 249 | 0.030 |
Why?
|
Speech Perception | 1 | 1995 | 71 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-abl | 1 | 2014 | 30 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2015 | 155 | 0.030 |
Why?
|
Hindlimb | 1 | 1995 | 89 | 0.030 |
Why?
|
Chronic Disease | 3 | 2015 | 972 | 0.030 |
Why?
|
Video Recording | 1 | 2015 | 190 | 0.030 |
Why?
|
DNA, Viral | 2 | 2000 | 265 | 0.030 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 1999 | 568 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 1999 | 1938 | 0.030 |
Why?
|
Color Perception | 1 | 1995 | 117 | 0.030 |
Why?
|
Medical History Taking | 1 | 1994 | 80 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2009 | 915 | 0.030 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1994 | 173 | 0.030 |
Why?
|
Carcinoid Tumor | 1 | 1994 | 42 | 0.030 |
Why?
|
Mathematics | 1 | 1994 | 190 | 0.030 |
Why?
|
Leg | 1 | 1994 | 137 | 0.030 |
Why?
|
China | 1 | 2014 | 228 | 0.030 |
Why?
|
Allografts | 1 | 2014 | 172 | 0.030 |
Why?
|
Ultrasonography | 1 | 1996 | 692 | 0.030 |
Why?
|
Up-Regulation | 1 | 2016 | 717 | 0.030 |
Why?
|
Paraffin Embedding | 1 | 1993 | 78 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2013 | 116 | 0.030 |
Why?
|
Biological Assay | 1 | 1993 | 79 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2000 | 3111 | 0.030 |
Why?
|
Hand Strength | 2 | 2004 | 51 | 0.030 |
Why?
|
Simvastatin | 1 | 2013 | 106 | 0.030 |
Why?
|
Rectal Neoplasms | 1 | 1994 | 116 | 0.030 |
Why?
|
Conditioning, Operant | 1 | 1973 | 73 | 0.030 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2018 | 931 | 0.030 |
Why?
|
Heart Valves | 1 | 2012 | 23 | 0.030 |
Why?
|
Phosphoglycerate Kinase | 1 | 1992 | 17 | 0.030 |
Why?
|
Meprobamate | 3 | 1971 | 3 | 0.030 |
Why?
|
Phenobarbital | 3 | 1971 | 33 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2017 | 2839 | 0.030 |
Why?
|
Vibrissae | 2 | 2002 | 10 | 0.030 |
Why?
|
Cholangitis, Sclerosing | 1 | 1992 | 52 | 0.030 |
Why?
|
Cytoplasm | 1 | 1972 | 282 | 0.030 |
Why?
|
Hallucinogens | 1 | 1973 | 71 | 0.030 |
Why?
|
Adrenergic Agents | 2 | 1961 | 6 | 0.030 |
Why?
|
Meiosis | 1 | 1992 | 80 | 0.030 |
Why?
|
Posture | 2 | 2002 | 125 | 0.030 |
Why?
|
X Chromosome | 1 | 1992 | 152 | 0.020 |
Why?
|
Brain Stem | 2 | 2002 | 165 | 0.020 |
Why?
|
Statistics as Topic | 3 | 1989 | 238 | 0.020 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2011 | 36 | 0.020 |
Why?
|
Lipoproteins, LDL | 1 | 2011 | 83 | 0.020 |
Why?
|
Urea | 1 | 1971 | 58 | 0.020 |
Why?
|
Microcomputers | 1 | 1991 | 26 | 0.020 |
Why?
|
Jaw, Edentulous | 1 | 1990 | 6 | 0.020 |
Why?
|
Task Performance and Analysis | 1 | 1991 | 86 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2010 | 96 | 0.020 |
Why?
|
Glutamates | 1 | 1990 | 89 | 0.020 |
Why?
|
4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid | 1 | 1990 | 3 | 0.020 |
Why?
|
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 1990 | 17 | 0.020 |
Why?
|
Calcimycin | 1 | 1990 | 33 | 0.020 |
Why?
|
Technology | 1 | 2010 | 29 | 0.020 |
Why?
|
Cell Nucleus | 1 | 1972 | 581 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2010 | 26 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2010 | 155 | 0.020 |
Why?
|
Nervous System | 1 | 1990 | 87 | 0.020 |
Why?
|
Communication | 1 | 1994 | 440 | 0.020 |
Why?
|
Stress, Psychological | 1 | 1993 | 314 | 0.020 |
Why?
|
Injections, Intraperitoneal | 1 | 1990 | 102 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 1990 | 137 | 0.020 |
Why?
|
Hormones | 1 | 2010 | 141 | 0.020 |
Why?
|
Mammography | 1 | 1993 | 463 | 0.020 |
Why?
|
International Cooperation | 1 | 2010 | 127 | 0.020 |
Why?
|
Heart | 2 | 1971 | 557 | 0.020 |
Why?
|
Intergenerational Relations | 1 | 2009 | 5 | 0.020 |
Why?
|
Lithium | 1 | 1969 | 59 | 0.020 |
Why?
|
History, 21st Century | 1 | 2010 | 175 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2010 | 369 | 0.020 |
Why?
|
Electric Conductivity | 1 | 1969 | 144 | 0.020 |
Why?
|
Sleep | 4 | 1971 | 444 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 1999 | 2438 | 0.020 |
Why?
|
HIV-2 | 1 | 1988 | 4 | 0.020 |
Why?
|
Public Health | 1 | 2010 | 129 | 0.020 |
Why?
|
Proviruses | 1 | 1988 | 15 | 0.020 |
Why?
|
Public Policy | 1 | 2009 | 52 | 0.020 |
Why?
|
Geography | 1 | 2010 | 223 | 0.020 |
Why?
|
History, 20th Century | 1 | 2010 | 312 | 0.020 |
Why?
|
Rabbits | 5 | 1973 | 638 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2010 | 176 | 0.020 |
Why?
|
Pulmonary Ventilation | 1 | 2008 | 32 | 0.020 |
Why?
|
Alcoholism | 1 | 1990 | 172 | 0.020 |
Why?
|
Internship and Residency | 1 | 2018 | 1010 | 0.020 |
Why?
|
Myocardial Revascularization | 1 | 2008 | 31 | 0.020 |
Why?
|
Fluoroscopy | 1 | 2008 | 117 | 0.020 |
Why?
|
Health Status Indicators | 1 | 2009 | 105 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1988 | 78 | 0.020 |
Why?
|
Pharmacology | 2 | 1965 | 11 | 0.020 |
Why?
|
Dipyridamole | 1 | 2008 | 14 | 0.020 |
Why?
|
Neonicotinoids | 1 | 2008 | 1 | 0.020 |
Why?
|
Gestures | 1 | 1988 | 10 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2010 | 361 | 0.020 |
Why?
|
Neural Pathways | 1 | 1990 | 311 | 0.020 |
Why?
|
Internet | 1 | 2010 | 312 | 0.020 |
Why?
|
Maternal-Fetal Exchange | 1 | 2008 | 76 | 0.020 |
Why?
|
Speech Acoustics | 1 | 1988 | 22 | 0.020 |
Why?
|
HIV-1 | 1 | 1988 | 164 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2010 | 448 | 0.020 |
Why?
|
Age Distribution | 2 | 1998 | 204 | 0.020 |
Why?
|
Immunosuppressive Agents | 2 | 2004 | 977 | 0.020 |
Why?
|
Injections, Subcutaneous | 2 | 2006 | 117 | 0.020 |
Why?
|
Anxiety | 2 | 1971 | 286 | 0.020 |
Why?
|
Proteins | 1 | 1972 | 777 | 0.020 |
Why?
|
Laparoscopy | 1 | 1994 | 754 | 0.020 |
Why?
|
Electrocardiography | 1 | 2009 | 478 | 0.020 |
Why?
|
Mineralocorticoid Receptor Antagonists | 1 | 2007 | 59 | 0.020 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2006 | 11 | 0.020 |
Why?
|
Child, Preschool | 2 | 2006 | 3612 | 0.020 |
Why?
|
Cognition | 1 | 1991 | 571 | 0.020 |
Why?
|
Infusion Pumps, Implantable | 1 | 2006 | 25 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2007 | 153 | 0.020 |
Why?
|
Colitis, Ulcerative | 1 | 1992 | 711 | 0.020 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2005 | 12 | 0.020 |
Why?
|
Strikes, Employee | 1 | 1984 | 1 | 0.020 |
Why?
|
Alcohols | 1 | 1964 | 14 | 0.020 |
Why?
|
Cell Death | 1 | 2006 | 257 | 0.020 |
Why?
|
Codes of Ethics | 1 | 2004 | 12 | 0.020 |
Why?
|
Marketing of Health Services | 1 | 2004 | 15 | 0.020 |
Why?
|
Equipment Safety | 1 | 2004 | 31 | 0.020 |
Why?
|
Dysarthria | 1 | 2004 | 6 | 0.020 |
Why?
|
Paranoid Disorders | 1 | 2004 | 5 | 0.020 |
Why?
|
Quadriplegia | 1 | 2004 | 22 | 0.020 |
Why?
|
Nystagmus, Pathologic | 1 | 2004 | 33 | 0.020 |
Why?
|
Social Responsibility | 1 | 2004 | 57 | 0.020 |
Why?
|
Human Experimentation | 1 | 2004 | 39 | 0.020 |
Why?
|
Environment | 1 | 1966 | 219 | 0.020 |
Why?
|
Fecal Incontinence | 1 | 2004 | 57 | 0.020 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2004 | 21 | 0.020 |
Why?
|
Conflict of Interest | 1 | 2004 | 67 | 0.020 |
Why?
|
Malpractice | 1 | 2004 | 57 | 0.020 |
Why?
|
Vertigo | 1 | 2004 | 42 | 0.020 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2004 | 46 | 0.020 |
Why?
|
Drug Industry | 1 | 2004 | 54 | 0.010 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2004 | 66 | 0.010 |
Why?
|
Caregivers | 1 | 2005 | 151 | 0.010 |
Why?
|
Truth Disclosure | 1 | 2004 | 87 | 0.010 |
Why?
|
Prednisone | 1 | 2004 | 258 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 243 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2004 | 299 | 0.010 |
Why?
|
Postmenopause | 1 | 2004 | 98 | 0.010 |
Why?
|
Population Surveillance | 1 | 2005 | 219 | 0.010 |
Why?
|
Syndrome | 1 | 2004 | 446 | 0.010 |
Why?
|
Anxiety Disorders | 1 | 1964 | 147 | 0.010 |
Why?
|
Graft Survival | 2 | 2000 | 885 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1992 | 1928 | 0.010 |
Why?
|
Sodium Chloride | 2 | 1973 | 88 | 0.010 |
Why?
|
Acetylcholine | 1 | 2003 | 176 | 0.010 |
Why?
|
Endpoint Determination | 1 | 2003 | 60 | 0.010 |
Why?
|
Physical Stimulation | 1 | 2002 | 70 | 0.010 |
Why?
|
Government | 1 | 2002 | 9 | 0.010 |
Why?
|
Urinary Incontinence | 1 | 2004 | 206 | 0.010 |
Why?
|
Arteriosclerosis | 1 | 2002 | 113 | 0.010 |
Why?
|
Binding, Competitive | 1 | 2002 | 146 | 0.010 |
Why?
|
Technology Assessment, Biomedical | 1 | 2002 | 27 | 0.010 |
Why?
|
State Government | 1 | 2002 | 20 | 0.010 |
Why?
|
Ligands | 1 | 2003 | 433 | 0.010 |
Why?
|
Orientation | 1 | 2002 | 119 | 0.010 |
Why?
|
Body Mass Index | 1 | 2005 | 768 | 0.010 |
Why?
|
Accreditation | 1 | 2002 | 60 | 0.010 |
Why?
|
Hexamethonium Compounds | 1 | 2001 | 6 | 0.010 |
Why?
|
Choline O-Acetyltransferase | 1 | 2001 | 23 | 0.010 |
Why?
|
Consciousness | 1 | 1961 | 26 | 0.010 |
Why?
|
Administration, Cutaneous | 1 | 2001 | 58 | 0.010 |
Why?
|
Volition | 1 | 2001 | 15 | 0.010 |
Why?
|
Lysergic Acid Diethylamide | 3 | 1973 | 22 | 0.010 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2000 | 24 | 0.010 |
Why?
|
Rehabilitation | 1 | 2000 | 5 | 0.010 |
Why?
|
Medical Audit | 1 | 2000 | 40 | 0.010 |
Why?
|
New York | 1 | 2000 | 69 | 0.010 |
Why?
|
Cadaver | 1 | 2000 | 184 | 0.010 |
Why?
|
International Normalized Ratio | 1 | 2000 | 38 | 0.010 |
Why?
|
Signal Transduction | 1 | 2010 | 3267 | 0.010 |
Why?
|
Documentation | 1 | 2000 | 97 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2002 | 222 | 0.010 |
Why?
|
Cimetidine | 1 | 1979 | 7 | 0.010 |
Why?
|
Schizophrenia | 3 | 1968 | 464 | 0.010 |
Why?
|
Pruritus | 1 | 1979 | 26 | 0.010 |
Why?
|
Virus Replication | 1 | 2000 | 319 | 0.010 |
Why?
|
Granuloma | 1 | 1998 | 65 | 0.010 |
Why?
|
Utilization Review | 1 | 1997 | 21 | 0.010 |
Why?
|
Insurance, Health | 1 | 1998 | 160 | 0.010 |
Why?
|
Delphi Technique | 1 | 1997 | 80 | 0.010 |
Why?
|
Tissue Donors | 1 | 2000 | 465 | 0.010 |
Why?
|
Fluconazole | 1 | 1997 | 10 | 0.010 |
Why?
|
Deanol | 3 | 1970 | 3 | 0.010 |
Why?
|
Amphotericin B | 1 | 1997 | 34 | 0.010 |
Why?
|
Chlorpromazine | 2 | 1968 | 14 | 0.010 |
Why?
|
Pentobarbital | 2 | 1967 | 20 | 0.010 |
Why?
|
Health Care Costs | 1 | 1998 | 238 | 0.010 |
Why?
|
Base Sequence | 2 | 1992 | 2335 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 1992 | 3035 | 0.010 |
Why?
|
Social Support | 1 | 1997 | 193 | 0.010 |
Why?
|
Writing | 1 | 1995 | 29 | 0.010 |
Why?
|
Blood Loss, Surgical | 1 | 1995 | 112 | 0.010 |
Why?
|
Electric Stimulation | 1 | 1975 | 347 | 0.010 |
Why?
|
Graft Rejection | 1 | 2000 | 1065 | 0.010 |
Why?
|
Auditory Perception | 1 | 1995 | 96 | 0.010 |
Why?
|
Temporal Lobe | 1 | 1995 | 173 | 0.010 |
Why?
|
Sensation | 1 | 1994 | 45 | 0.010 |
Why?
|
Peritoneum | 1 | 1994 | 57 | 0.010 |
Why?
|
Intraoperative Care | 1 | 1994 | 82 | 0.010 |
Why?
|
Psychopharmacology | 1 | 1973 | 26 | 0.010 |
Why?
|
Suture Techniques | 1 | 1994 | 134 | 0.010 |
Why?
|
Nuclear Transfer Techniques | 1 | 1972 | 15 | 0.010 |
Why?
|
Amoeba | 1 | 1972 | 5 | 0.010 |
Why?
|
Death | 1 | 1993 | 74 | 0.010 |
Why?
|
Tritium | 1 | 1972 | 133 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1972 | 274 | 0.010 |
Why?
|
Deoxyribonuclease HpaII | 1 | 1992 | 1 | 0.010 |
Why?
|
Electrodes, Implanted | 1 | 1973 | 171 | 0.010 |
Why?
|
Sex Determination Analysis | 1 | 1992 | 18 | 0.010 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 1992 | 30 | 0.010 |
Why?
|
Oogenesis | 1 | 1992 | 45 | 0.010 |
Why?
|
Restriction Mapping | 1 | 1992 | 157 | 0.010 |
Why?
|
Models, Neurological | 1 | 1995 | 405 | 0.010 |
Why?
|
Colonoscopy | 1 | 1994 | 267 | 0.010 |
Why?
|
Sleep Stages | 1 | 1971 | 45 | 0.010 |
Why?
|
Pain | 1 | 1994 | 390 | 0.010 |
Why?
|
Oligonucleotides | 1 | 1992 | 92 | 0.010 |
Why?
|
Stress, Physiological | 1 | 1973 | 227 | 0.010 |
Why?
|
Germ Cells | 1 | 1992 | 126 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 1992 | 204 | 0.010 |
Why?
|
Pulse | 1 | 1971 | 18 | 0.010 |
Why?
|
Genes | 1 | 1992 | 305 | 0.010 |
Why?
|
Plant Extracts | 1 | 1973 | 244 | 0.010 |
Why?
|
Methylation | 1 | 1992 | 251 | 0.010 |
Why?
|
Gestational Age | 1 | 1992 | 312 | 0.010 |
Why?
|
DMF Index | 1 | 1990 | 1 | 0.010 |
Why?
|
Oral Hygiene | 1 | 1990 | 3 | 0.010 |
Why?
|
Dental Plaque Index | 1 | 1990 | 3 | 0.010 |
Why?
|
Periodontal Index | 1 | 1990 | 4 | 0.010 |
Why?
|
MMPI | 1 | 1970 | 11 | 0.010 |
Why?
|
Sleep, REM | 1 | 1970 | 50 | 0.010 |
Why?
|
Alcoholic Intoxication | 1 | 1990 | 31 | 0.010 |
Why?
|
Desipramine | 1 | 1970 | 9 | 0.010 |
Why?
|
Psychological Tests | 1 | 1970 | 91 | 0.010 |
Why?
|
Wakefulness | 1 | 1970 | 134 | 0.010 |
Why?
|
Hypothalamus | 1 | 1970 | 79 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1992 | 930 | 0.010 |
Why?
|
Amygdala | 1 | 1970 | 84 | 0.010 |
Why?
|
Heparinoids | 1 | 1989 | 4 | 0.010 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 1988 | 25 | 0.010 |
Why?
|
DNA Probes | 1 | 1988 | 77 | 0.010 |
Why?
|
Molecular Weight | 1 | 1989 | 332 | 0.010 |
Why?
|
Blotting, Southern | 1 | 1988 | 129 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1988 | 303 | 0.010 |
Why?
|
Gene Amplification | 1 | 1988 | 131 | 0.010 |
Why?
|
Thiopental | 1 | 1967 | 15 | 0.000 |
Why?
|
Blotting, Western | 1 | 1988 | 786 | 0.000 |
Why?
|
DNA | 1 | 1992 | 1295 | 0.000 |
Why?
|
Social Isolation | 1 | 1966 | 67 | 0.000 |
Why?
|
Orphenadrine | 1 | 1965 | 2 | 0.000 |
Why?
|
Perphenazine | 1 | 1965 | 2 | 0.000 |
Why?
|
Barbiturates | 1 | 1965 | 12 | 0.000 |
Why?
|
Drug Therapy | 1 | 1965 | 70 | 0.000 |
Why?
|
Caffeine | 1 | 1965 | 81 | 0.000 |
Why?
|
Hospitals, University | 1 | 1984 | 194 | 0.000 |
Why?
|
Amino Alcohols | 1 | 1963 | 1 | 0.000 |
Why?
|
Choline | 1 | 1963 | 23 | 0.000 |
Why?
|
Stimulation, Chemical | 2 | 1970 | 63 | 0.000 |
Why?
|
Cholestasis | 1 | 1979 | 47 | 0.000 |
Why?
|
Injections, Intramuscular | 2 | 1968 | 63 | 0.000 |
Why?
|
Depression, Chemical | 1 | 1970 | 29 | 0.000 |
Why?
|
5-Hydroxytryptophan | 1 | 1970 | 6 | 0.000 |
Why?
|